Microcirculation

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
2 programs
Omnilux new-UN/A1 trial
Photobiomodulation - Blue WavelengthN/A1 trial
Active Trials
NCT03357523Completed20Est. Dec 2019
NCT07338695Enrolling By Invitation40Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Jerusalem PharmaceuticalsPhotobiomodulation - Blue Wavelength
Jerusalem PharmaceuticalsOmnilux new-U

Clinical Trials (2)

Total enrollment: 60 patients across 2 trials

NCT07338695Jerusalem PharmaceuticalsPhotobiomodulation - Blue Wavelength

The Effect of Photobiomodulation on Microvascular Blood Flow: The Role of Wavelength and Skin Temperature

Start: Jan 2026Est. completion: Dec 202840 patients
N/AEnrolling By Invitation

Evaluation of Peripheral Microcirculation Hemodynamics Following Various Changes Based on Noninvasive Thermography

Start: Nov 2017Est. completion: Dec 201920 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space